New injection aims to tame stubborn autoimmune diseases
NCT ID NCT07614191
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug, GT801, in 22 adults with moderate to severe autoimmune diseases that haven't responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug helps control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Renji Hospital
RECRUITINGShanghai, Shanghai Municipality, 200127, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal kidney damage in lupus — no biopsy needed?
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a smarter antibody outsmart a kidney disease that resists standard treatment?
- Can a new biologic tame lupus flares?
- Could a single injection tame lupus and Sjögren's?
- Can a single infusion tame tough lupus?